Inhibitory effects of Nabumetone, a cyclooxygenase-2 inhibitor, and esculetin, a lipoxygenase inhibitor, on N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats

Japanese Journal of Cancer Research

Volumn 89, Issue 5, 1998, Pages 496-501

  Matsunaga, Kengo ^a   Yoshimi, Naoki ^a   Yamada, Yasuhiro ^a   Shimizu, Masahito ^a   Kawabata, Kunihiro ^a   Ozawa, Yuki ^a   Hara, Akira ^a   Mori, Hideki ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

Chemoprevention; Cyclooxygenase 2; Lipoxygenase; Rat mammary carcinogenesis

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; ESCULETIN; LIPOXYGENASE INHIBITOR; METHYLNITROSOUREA; NABUMETONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER INCIDENCE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; FEMALE; LIVER WEIGHT; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031839421     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb03289.x     Document Type: Article

References (41)

1. Bennett, A., Charlier, E. M., McDonald, A. M., Simpson, J. S., Stamford, I. F. and Zebro, T. Prostaglandins and breast cancer. Lancet, ii, 624-626 (1977).
2. Bennett, A. The production of prostanoids in human cancers, and their implications for tumor progression. Prog. Lipid Res., 25, 539-542 (1986).
3. Jung, T. T. K., Berlinger, N. T. and Juhn, S. K. Prostaglandins in squamous cell carcinoma of the head and neck: a preliminary study. Laryngoscope, 95, 307-312 (1985).
4. Bennett, A., Carroll, M. A., Stamford, I. F., Whimster, W. F. and Williams, F. Prostaglandins and human lung carcinomas. Br. J. Cancer, 46, 888-893 (1982).
5. Bennett, A., Civier, A., Hensby, C. N., Melhuish, P. B. and Stamford, I. F. Measurement of arachidonate and its metabolites extracted from human normal and malignant gastrointestinal tissues. Gut, 28, 315-318 (1987).
6. Rigas, B., Goldman, I. S. and Levine, L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med., 122, 518-523 (1993).
7. Mclemore, T. L., Hubbard, W. C., Litterst, C. L., Liu, M. C., Miller, S., McMahon, N. A., Eggleston, J. C. and Boyd, M. R. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res., 48, 3140-3147 (1988).
8. Reddy, B., Rao, C., Rivenson, A. and Kelloff, G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis, 14, 1493-1497 (1993).
9. Reddy, B., Maruyama, H. and Kelloff, G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumor development. Cancer Res., 47, 5340-5346 (1987).
10. Rao, C., Rivenson, A., Simi, B., Zang, E., Kelloff, G., Steele, V. and Reddy, B. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res., 55, 1464-1472 (1995).
11. Marnett, L. J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res., 52, 5575-5589 (1992).
12. Reddy, B. S., Rao, C. V. and Seibert, K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res., 56, 4566-4569 (1996).
13. Takahashi, M., Fukutake, M., Yokota, S., Ishida, K., Wakabayashi, K. and Sugimura, T. Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2. J. Cancer Res. Clin. Oncol., 122, 219-222 (1996).
14. Yoshimi, N., Kawabata, K., Hara, A., Matsunaga, K., Yamada, Y. and Mori, H. Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats. Jpn. J. Cancer Res., 88, 1044-1051 (1997).
15. Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S. and DuBois, R. N. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterolohgy, 107, 1183-1188 (1994).
16. Jones, D. A., Carlton, D. P., Mcintyre, T. M., Zimmerman, G. A. and Prescott, S. M. Molecular cloning of human prostaglandin endoperoxide synthases type II and demonstration of expression in response to cytolines. J. Biol. Chem., 268, 9049-9054 (1993).
17. Seibert, K., Zhang, Y., Leahy, K., Hauser, S., Masferrer, J., Perkins, W., Lee, L. and Isakson, P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. USA, 91, 12013-12017 (1994).
18. Barnnett, J., Chow, J., Ives, D., Chiou, M., Mackenzie, R., Osen, E., Nguyen, B., Tsing, S., Bach, C. and Freire, J. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim. Biophys. Acta, 1209, 130-139 (1994).
19. Laneuvill, O., Breuer, D. K., Dewitt, D. L., Hla, T., Funk, C. D. and Smith, W. L. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by non-steroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther., 271, 927-934 (1994).
20. Griswold, D. E. and Adams, J. L. Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date. Med. Res. Rev., 16, 181-206 (1996).
21. Spangler, R. S. Cyclooxygenase 1 and 2 in rheumatic disease: implications for nonsteroidal anti-inflammatory drug therapy. Semin. Arthritis Rheum., 26, 435-445 (1996).
22. Lee, P. P. and Ip, M. M. Regulation of proliferation of rat mammary tumor cells by inhibitors of cyclooxygenase and lipoxygenase. Prostaglandins Leukot. Essent. Fatty Acids, 45, 21-31 (1992).
23. Rose, D. P. and Connoly, J. M. Effects of fatty acids and inhibitors of eicosanoid synthesis on the growth of a human breast cancer cell line in culture. Cancer Res., 50, 7139-7144 (1990).
24. Kitagawa, H. and Noguchi, M. Comparative effects of piroxicam and esculetin on incidence, proliferation, and cell kinetics of mammary carcinomas induced by 7,12-dimethylbenz[a]anthracene in rats on high-and low-diets. Oncology, 51, 401-410 (1994).
25. Thompson, H. J. and Meeker, L. D. Induction of mammary gland carcinomas by the subcutaneous injection of Imethyl-1-nitrosourea. Cancer Res., 43, 1628-1629 (1983).
26. Wood, G. S. and Warnke, R. Endogenous avidin-binding activity in tissues and its relevance to biotin-avidin detection systems. J. Histochem. Cytochem., 29, 1196-1204 (1981).
27. Broder, S. Perspectives on cancer in Japan and the United States. Jpn. J. Cancer Res., 84, 821-830 (1993).
28. Thompson, H. J., Briggs, S., Paranka, N. S., Piazza, G. A., Brendel, K., Gross, P. H., Sperl, G. J., Pamukcu, R. and Ahnen, D. J. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J. Natl. Cancer Inst., 87, 1259-1260 (1995).
29. McCormick, D. L. and Moon, R. C. Indomethacin inhibits mammary carcinogenesis in rats. Proc. Int. Assoc. Breast Cancer Res., 1, 43 (1983).
30. McCormick, D. L. and Moon, R. C. Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal antiinflammatory agent. Br. J. Cancer, 48, 859-861 (1983).
31. Thompson, H. J., Jiang, C., Lu, J., Mehta, R. G., Piazza, G. A., Paranka, N. S., Pamukcu, R. and Ahnen, D. J. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res., 57, 267-271 (1997).
32. Hara, A., Yoshimi, N., Niwa, M., Ino, N. and Mori, H. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn. J. Cancer Res., 88, 600-604 (1997).
33. Ohshima, H. and Bartsch, H. Chronic infections and inflammatory processes as cancer risk factors. Mutat. Res., 305, 253-264 (1994).
34. Lewis, J. G. and Adams, D. O. Inflammation, oxidative DNA damage, and carcinogenesis. Environ. Health Perspect., 76, 19-27 (1987).
35. Lewis, J. G., Hamilton, T. and Adams, D. O. The effect of macrophage development on the release of reactive oxygen intermediates and lipid oxidation products, and their ability to induce oxidative DNA damage in mammalian cells. Carcinogenesis, 7, 813-818 (1986).
36. 2 and cyclooxygenase, in the large bowel mucosa and neoplasms of F344 rats treated with naturally occurring carcinogen, 1-hydroxyanthraquinone. Cancer Lett., 97, 75-82 (1995).
37. Yoshimi, N., Sato, S., Makita, H., Wang, A., Hirose, Y., Tanaka, T. and Mori, H. Expression of cytokines, TNF-alpha and IL-1 alpha, in MAM acetate and 1-hydroxyan-thraquinone-induced colon carcinogenesis of rats. Carcinogenesis, 15, 783-785 (1994).
38. A716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803-809 (1996).
39. Nakatsugi, S., Fukutake, M., Takahashi, M., Fukuda, K., Isoi, T., Taniguchi, Y., Sugimura, T. and Wakabayashi, K. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase inhibitor, in Min mice. Jpn. J. Cancer Res., 88, 1117-1120 (1997).
40. Buckman, D. K., Hubbard, N. E. and Erickson, K. L. Eicosanoids and linoleate-enhanced growth of mouse mammary tumor cell. Prostaglandins Leukot. Essent. Fatty Acids, 44, 177-184 (1991).
41. Blomgren, H. and Andersson, G. K. Growth inhibition of human malignant glioma cells in vitro by agents which interfere with biosynthesis of eicosanoids. Anticancer Res., 12, 981-986 (1992).